Several solid and liquid cancer types overexpress P2X7, for which P2X7-targeting drugs are potential therapeutic tools; these include acute myeloid and chronic lymphocytic leukemia [9,42,60,61,62,63], melanoma [43,64,65], glioma [66,67,68], neuroblastoma [41,44,55,69,70] prostate, breast, bone, and colorectal cancer [71,72,73,74,75,76,77]. This evidence concerns the gene P2RX7 and central nervous system cancer.